RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive lymphoma: drug combo aims to unmask cancer cells
Disease control OngoingThis study tests a combination of two drugs (TTI-622 and pembrolizumab) in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. The drugs work by helping the immune system recognize and attack cancer cells. The goal is to find …
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC